Accession Number:

ADA434806

Title:

99-Technetium Sestamibi Scanning to Predict the Efficacy of Estramustine Phosphate in Overcoming Paclitaxel Resistance in Patients with Advanced Breast Cancer

Descriptive Note:

Final rept. 1 Sep 1999-31 Aug 2004

Corporate Author:

NEW YORK UNIV NY SCHOOL OF MEDICINE

Personal Author(s):

Report Date:

2004-09-01

Pagination or Media Count:

6.0

Abstract:

The purpose of this research was to investigate the ability of 99-Technetium Sestamibi Tc-99-SM to serve as a non-invasive means of assessing the presence of clinically relevant drug resistance in patients with advanced breast cancer. Tc-99-SM is a substrate of the p-glycoprotein, the transmembrane drug efflux transporter involved in classic multi-drug resistance MDR. We proposed to the hypothesis that rapid clearance of Tc-99-SM correlates with the presence of functional MDR and can be used to predict which patients will have tumors resistant to chemotherapy drugs that are MDR substrates. We also proposed investigating whether changes in the tumor clearance of 99-Tc-SM observed before and after the administration of an MDR inhibitor, could predict whether the inhibitor can overcome clinical drug resistance in an individual patient.

Subject Categories:

  • Anatomy and Physiology
  • Medicine and Medical Research
  • Pharmacology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE